In patients with hypertrophic cardiomyopathy and obstruction of the left ventricular outflow tract, nonsurgical reduction of the septum is a treatment option when medical therapy has failed. We ...

Boston, MA - A nonsurgical procedure to reduce the interventricular septum in patients with hypertrophic cardiomyopathy (HCM) produces sustained improvements in exercise capacity and reductions in ...

Researchers from the University of Alabama at Birmingham Marnix E. Heersink School of Medicine have published a study in the Journal of the American Heart Association that focuses on how the volume of ...

"Older patients often tolerate medications poorly and younger patients may feel lethargic and tired with beta blockers and calcium channel blockers. These patients would be appropriate candidates for ...

WASHINGTON – Treatment with investigational mavacamten allowed patients with advanced obstructive hypertrophic cardiomyopathy (oHCM) to avoid septal reduction therapies (SRT), a researcher reported.

SOUTH SAN FRANCISCO, Calif., Sept. 10, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today announced that it will study mavacamten as a therapeutic alternative to septal reduction therapy ...

Please provide your email address to receive an email when new articles are posted on . Mavacamten (Bristol Myers Squibb) also improved symptoms, biomarker levels and quality of life metrics compared ...

Please provide your email address to receive an email when new articles are posted on . In patients with obstructive hypertrophic cardiomyopathy, septal reduction therapy was associated with reduced ...

There are 2 methods of reducing the left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy. They are: surgical resection and ethanol injection into the septal branch ...

Hypertrophic cardiomyopathy is an inherited condition that affects up to 750,000 people in the United States. It often involves left ventricular outflow tract obstruction. Septal reduction therapies ...

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced results from the Phase 3 VALOR-HCM study, which showed the addition of mavacamten, an investigational, first-in-class ...

WASHINGTON, DC (UPDATED)—Among patients with obstructive hypertrophic cardiomyopathy (HCM) who are candidates for surgical or interventional septal reduction therapy (SRT) despite being on maximally ...